A Study to Investigate Effectiveness of Tirzepatide Following Initiation of Ixekizumab in
The main purpose of this study is to assess the effectiveness of adding tirzepatide to ixekizumab therapy in standard clinical practice in participants with active PsA and obesity or overweight with at least 1 weight-related comorbidity. The study will last up to 12 months.
| Condition(s) | Psoriatic Arthritis, Overweight or Obesity |
|---|---|
| Status | Recruiting |
| Phase | Phase 4 |
| Study type | Interventional |
| Summary | The main purpose of this study is to assess the effectiveness of adding tirzepatide to ixekizumab therapy in standard clinical practice in participants with active PsA and obesity or overweight with at least 1 weight-related comorbidity. The study will last up to 12 months. |
| Who can participate | Inclusion Criteria: * Have a diagnosis of active psoriatic arthritis (PsA) as defined by a rheumatologist or other healthcare professional (HCP) experienced in treating PsA. * Body Mass Index (BMI) of 30 kilograms per meter squared (kg/m²) or greater (obesity) or 27 kg/m2 to \<30 kg/m² (overweight) in the presence of at least 1 weight-related comorbid condition (hypertension, dyslipidemia, type 2 diabetes, obstructive sleep apnea, or cardiovascular disease). * Who have been treated with ixekizumab for approximately 3 months (±1 month) prior to decision to add tirzepatide. * Must be able to initiate tirzepatide (Day 0) within 30 days of treatment decision (baseline or screening). Exclusion Criteria: * Have currently received ixekizumab for more than 4 months or less than 2 months. * Had any |
| Ages | 18 Years |
| Sex | All |
| Lead sponsor | Eli Lilly and Company |
| Locations | Avondale, Arizona, United States; Chandler, Arizona, United States; Flagstaff, Arizona, United States; Gilbert, Arizona, United States; Glendale, Arizona, United States; Mesa, Arizona, United States (+49 more sites) |
| Start date | 2025-03-06 |
| NCT ID | NCT06864026 |
| Official listing | https://clinicaltrials.gov/study/NCT06864026 |